|Last Price$157.48||Day Change (%)-3.63%|
|Open Price$162.43||Day Change ($)-5.94|
|Day Range155.06–163.33||52-Week Range142.02–208.88|
As of Tue 10/6/2015 1:27:00 PM | USD
Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of Soliris® (eculizumab) for the Prevention of Thrombotic Microangiopathy (TMA) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
10 stocks you should have bought the last time the Fed raised interest rates
Research and Markets: Dry (Atrophic) Macular Degeneration Market - Global Clinical Trials Review, H2, 2015
Research and Markets: Myasthenia Gravis Pipeline Review, H2 2015
We crunch the numbers to see which stocks are most widely held among analyst-recommended large-cap funds.
Ownership data provide a look at who else owns the company.
Standing out in a good year for stocks.
Buying a country or sector fund isn't as easy as it seems.
Alexion's diversifying pipeline and focus on attractive rare-disease markets are strengthening its competitive position.
Week ending Nov. 10: Investors remain optimistic about direction of economy.